In fact, compared with other potential anti-VEGF therapies (aflibercept and bevacizumab), ranibizumab has not been shown to be cost-effective in treatment of AMD, DME, and PM (64–66). The gene discussed is VEGFA; the disease is age-related macular degeneration.